Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Sci Adv ; 10(22): eadk9681, 2024 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-38820148

RESUMEN

In response to energy and nutrient shortage, the liver triggers several catabolic processes to promote survival. Despite recent progress, the precise molecular mechanisms regulating the hepatic adaptation to fasting remain incompletely characterized. Here, we report the identification of hydroxysteroid dehydrogenase-like 2 (HSDL2) as a mitochondrial protein highly induced by fasting. We show that the activation of PGC1α-PPARα and the inhibition of the PI3K-mTORC1 axis stimulate HSDL2 expression in hepatocytes. We found that HSDL2 depletion decreases cholesterol conversion to bile acids (BAs) and impairs FXR activity. HSDL2 knockdown also reduces mitochondrial respiration, fatty acid oxidation, and TCA cycle activity. Bioinformatics analyses revealed that hepatic Hsdl2 expression positively associates with the postprandial excursion of various BA species in mice. We show that liver-specific HSDL2 depletion affects BA metabolism and decreases circulating cholesterol levels upon refeeding. Overall, our report identifies HSDL2 as a fasting-induced mitochondrial protein that links nutritional signals to BAs and cholesterol homeostasis.


Asunto(s)
Ácidos y Sales Biliares , Colesterol , Hidroxiesteroide Deshidrogenasas , Animales , Humanos , Ratones , Ácidos y Sales Biliares/metabolismo , Colesterol/metabolismo , Ayuno/metabolismo , Hepatocitos/metabolismo , Homeostasis , Hígado/metabolismo , Diana Mecanicista del Complejo 1 de la Rapamicina/metabolismo , Mitocondrias/metabolismo , Transducción de Señal , Hidroxiesteroide Deshidrogenasas/genética , Hidroxiesteroide Deshidrogenasas/metabolismo
2.
JHEP Rep ; 5(12): 100904, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37942225

RESUMEN

Background & Aims: Hepatic encephalopathy (HE) is defined as a reversible syndrome and therefore should resolve following liver transplantation (LT). However, neurological complications have been reported in up to 47% of LT recipients, which have been documented to be associated with a history of overt HE pre-LT. We hypothesise that multiple episodes of HE lead to permanent cell injury and exacerbate neurological dysfunction. Our goal was to evaluate the impact of cumulative HE episodes on neurological status and brain integrity in rats with chronic liver disease. Methods: Episodes of overt HE (loss of righting reflex) were induced following injection of ammonium acetate in bile duct ligation (BDL) rats (BDL-Ammonia) every 4 days starting at week 3 post-BDL. Neurobehaviour was evaluated after the last episode. Upon sacrifice, plasma ammonia, systemic oxidative stress, and inflammation markers were assessed. Neuronal markers including neuron-specific nuclear antigen and SMI311 (anti-neurofilament marker) and apoptotic markers (cleaved caspase-3, Bax, and Bcl2) were measured. Total antioxidant capacity, oxidative stress marker (4-hydroxynonenal), and proinflammatory cytokines (tumour necrosis factor-alpha and interleukin-1ß) were measured in brain (hippocampus, frontal cortex, and cerebellum). Proteomic analysis was conducted in the hippocampus. Results: In hippocampus of BDL-Ammonia rats, cleaved caspase-3 and Bax/Bcl2 ratio were significantly increased, whereas NeuN and SMI311 were significantly decreased compared with BDL-Vehicle rats. Higher levels of oxidative stress-induced post-translational modified proteins were found in hippocampus of BDL-Ammonia group which were associated with a lower total antioxidant capacity. Conclusions: Ammonia-induced episodes of overt HE caused neuronal cell injury/death in BDL rats. These results suggest that multiple bouts of HE can be detrimental on the integrity of the brain, translating to irreversibility and hence neurological complications post-LT. Impact and implications: Hepatic encephalopathy (HE) is defined as a reversible neuropsychiatric syndrome resolving following liver transplantation (LT); however, ∼47% of patients demonstrate neurological impairments after LT, which are associated with a previous history of overt HE pre-LT. Our study indicates that multiple episodes of overt HE can cause permanent neuronal damage which may lead to neurological complications after LT. Nevertheless, preventing the occurrence of overt HE episodes is critical for reducing the risk of irreversible neuronal injury in patients with cirrhosis.

3.
J Neurochem ; 162(4): 337-351, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35771118

RESUMEN

Hepatic encephalopathy (HE) is a debilitating neurological complication of chronic liver disease (CLD). Hyperammonemia plays an important role in HE's pathogenesis, acting synergistically with systemic oxidative stress. During CLD, muscle plays a compensatory role in detoxifying ammonia, and therefore muscle loss leads to an increase in the risk of developing HE. With most animal studies involving males, sex's impact on the development of CLD and associated complications such as HE and muscle loss remains unknown. Therefore, we aimed to identify the impact of sex on CLD, HE, and muscle mass loss in a rodent model of CLD. Liver injury markers, hyperammonemia, oxidative stress, muscle mass, and ammonia clearance were measured in female and male bile-duct ligated (BDL) rats. In addition, covert HE was assessed in females while ammonia-precipitated severe HE was assessed in female and male BDL rats, and male BDL rats treated with allopurinol (100 mg/kg), an antioxidant (xanthine oxidase inhibitor). Female BDL developed CLD and HE (impaired motor coordination and night activity) compared to respective SHAM. Hyperammonemia and muscle ammonia clearance were similar between female and male BDL. However, only female BDL rats did not develop muscle loss, brain edema, and short-term memory impairment (vs. female SHAM) and systemic oxidative stress and decreased albumin levels (vs. male BDL). Furthermore, both female BDL and allopurinol-treated male BDL rats were protected against ammonia-induced overt HE. In conclusion, female and male BDL rats develop distinct features of CLD and HE, with systemic oxidative stress playing a pivotal role in the susceptibility to ammonia-precipitated overt HE.


Asunto(s)
Encefalopatía Hepática , Hiperamonemia , Alopurinol , Amoníaco , Animales , Bilis , Modelos Animales de Enfermedad , Femenino , Encefalopatía Hepática/etiología , Hiperamonemia/etiología , Masculino , Estrés Oxidativo , Ratas
4.
Ageing Res Rev ; 72: 101462, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34534683

RESUMEN

Alzheimer's disease (AD) is a complex age-related neurodegenerative disease, associated with central and peripheral metabolic anomalies, such as impaired glucose utilization and insulin resistance. These observations led to a considerable interest not only in lifestyle-related interventions, but also in repurposing insulin and other anti-diabetic drugs to prevent or treat dementia. Body temperature is the oldest known metabolic readout and mechanisms underlying its maintenance fail in the elderly, when the incidence of AD rises. This raises the possibility that an age-associated thermoregulatory deficit contributes to energy failure underlying AD pathogenesis. Brown adipose tissue (BAT) plays a central role in thermogenesis and maintenance of body temperature. In recent years, the modulation of BAT activity has been increasingly demonstrated to regulate energy expenditure, insulin sensitivity and glucose utilization, which could also provide benefits for AD. Here, we review the evidence linking thermoregulation, BAT and insulin-related metabolic defects with AD, and we propose mechanisms through which correcting thermoregulatory impairments could slow the progression and delay the onset of AD.


Asunto(s)
Enfermedad de Alzheimer , Enfermedades Neurodegenerativas , Tejido Adiposo Pardo/metabolismo , Anciano , Enfermedad de Alzheimer/metabolismo , Regulación de la Temperatura Corporal , Metabolismo Energético , Humanos , Enfermedades Neurodegenerativas/metabolismo , Termogénesis
5.
Hepatol Commun ; 5(3): 446-460, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33681678

RESUMEN

Obesity and diabetes are strongly associated not only with fatty liver but also cognitive dysfunction. Moreover, their presence, particularly in midlife, is recognized as a risk factor for Alzheimer's disease (AD). AD, the most common cause of dementia, is increasingly considered as a metabolic disease, although underlying pathogenic mechanisms remain unclear. The liver plays a major role in maintaining glucose and lipid homeostasis, as well as in clearing the AD neuropathogenic factor amyloid-ß (Aß) and in metabolizing cerebrosterol, a cerebral-derived oxysterol proposed as an AD biomarker. We hypothesized that liver impairment induced by obesity contributes to AD pathogenesis. We show that the AD triple transgenic mouse model (3xTg-AD) fed a chow diet presents a hepatic phenotype similar to nontransgenic controls (NTg) at 15 months of age. A high-fat diet (HFD), started at the age of 6 months and continued for 9 months, until sacrifice, induced hepatic steatosis in NTg, but not in 3xTg-AD mice, whereas HFD did not induce changes in hepatic fatty acid oxidation, de novo lipogenesis, and gluconeogenesis. HFD-induced obesity was associated with a reduction of insulin-degrading enzyme, one of the main hepatic enzymes responsible for Aß clearance. The hepatic rate of cerebrosterol glucuronidation was lower in obese 3xTg-AD than in nonobese controls (P < 0.05) and higher compared with obese NTg (P < 0.05), although circulating levels remained unchanged. Conclusion: Modulation of hepatic lipids, Aß, and cerebrosterol metabolism in obese 3xTg-AD mice differs from control mice. This study sheds light on the liver-brain axis, showing that the chronic presence of NAFLD and changes in liver function affect peripheral AD features and should be considered during development of biomarkers or AD therapeutic targets.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Dieta Alta en Grasa/efectos adversos , Hidroxicolesteroles/metabolismo , Hígado/metabolismo , Enfermedad de Alzheimer/etiología , Animales , Encéfalo/metabolismo , Eje Cerebro-Intestino/fisiología , Modelos Animales de Enfermedad , Lipogénesis/fisiología , Ratones , Ratones Obesos , Ratones Transgénicos
6.
Liver Int ; 41(5): 1020-1032, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33548108

RESUMEN

Hyperammonemia associated with chronic liver disease (CLD) is implicated in the pathogenesis of hepatic encephalopathy (HE). The gut is a major source of ammonia production that contributes to hyperammonemia in CLD and HE and remains the primary therapeutic target for lowering hyperammonemia. As an ammonia-lowering strategy, Escherichia coli Nissle 1917 bacterium was genetically modified to consume and convert ammonia to arginine (S-ARG). S-ARG was further modified to additionally synthesize butyrate (S-ARG + BUT). Both strains were evaluated in bile-duct ligated (BDL) rats; experimental model of CLD and HE. METHODS: One-week post-surgery, BDLs received non-modified EcN (EcN), S-ARG, S-ARG + BUT (3x1011 CFU/day) or vehicle until sacrifice at 3 or 5 weeks. Plasma (ammonia/pro-inflammatory/liver function), liver fibrosis (hydroxyproline), liver mRNA (pro-inflammatory/fibrogenic/anti-apoptotic) and colon mRNA (pro-inflammatory) biomarkers were measured post-sacrifice. Memory, motor-coordination, muscle-strength and locomotion were assessed at 5 weeks. RESULTS: In BDL-Veh rats, hyperammonemia developed at 3 and further increased at 5 weeks. This rise was prevented by S-ARG and S-ARG + BUT, whereas EcN was ineffective. Memory impairment was prevented only in S-ARG + BUT vs BDL-Veh. Systemic inflammation (IL-10/MCP-1/endotoxin) increased at 3 and 5 weeks in BDL-Veh. S-ARG + BUT attenuated inflammation at both timepoints (except 5-week endotoxin) vs BDL-Veh, whereas S-ARG only attenuated IP-10 and MCP-1 at 3 weeks. Circulating ALT/AST/ALP/GGT/albumin/bilirubin and gene expression of liver function markers (IL-10/IL-6/IL-1ß/TGF-ß/α-SMA/collagen-1α1/Bcl-2) were not normalized by either strain. Colonic mRNA (TNF-α/IL-1ß/occludin) markers were attenuated by synthetic strains at both timepoints vs BDL-Veh. CONCLUSION: S-ARG and S-ARG + BUT attenuated hyperammonemia, with S-ARG + BUT additional memory protection likely due to greater anti-inflammatory effect. These innovative strategies, particularly S-ARG + BUT, have potential to prevent HE.


Asunto(s)
Hiperamonemia , Animales , Bilis , Conductos Biliares , Modelos Animales de Enfermedad , Escherichia coli , Ligadura , Ratas
7.
J Neurochem ; 157(3): 561-573, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33382098

RESUMEN

Hepatic encephalopathy (HE) is a debilitating neurological complication of cirrhosis. By definition, HE is considered a reversible disorder, and therefore HE should resolve following liver transplantation (LT). However, persisting neurological complications are observed in as many as 47% of LT recipients. LT is an invasive surgical procedure accompanied by various perioperative factors such as blood loss and hypotension which could influence outcomes post-LT. We hypothesize that minimal HE (MHE) renders the brain frail and susceptible to hypotension-induced neuronal cell death. Six-week bile duct-ligated (BDL) rats with MHE and respective SHAM-controls were used. Several degrees of hypotension (mean arterial pressure of 30, 60 and 90 mm Hg) were induced via blood withdrawal from the femoral artery and maintained for 120 min. Brains were collected for neuronal cell count and apoptotic analysis. In a separate group, BDL rats were treated for MHE with the ammonia-lowering strategy ornithine phenylacetate (OP; MNK-6105), administered orally (1 g/kg) for 3 weeks before induction of hypotension. Hypotension 30 and 60 mm Hg (not 90 mm Hg) significantly decreased neuronal marker expression (NeuN) and cresyl violet staining in the frontal cortex compared to respective hypotensive SHAM-operated controls as well as non-hypotensive BDL rats. Neuronal degeneration was associated with an increase in cleaved caspase-3, suggesting the mechanism of cell death was apoptotic. OP treatment attenuated hyperammonaemia, improved anxiety and activity, and protected the brain against hypotension-induced neuronal cell death. Our findings demonstrate that rats with chronic liver disease and MHE are more susceptible to hypotension-induced neuronal cell degeneration. This highlights MHE at the time of LT is a risk factor for poor neurological outcome post-transplant and that treating for MHE pre-LT might reduce this risk.


Asunto(s)
Amoníaco/metabolismo , Conductos Biliares , Hipotensión/patología , Enfermedades Neurodegenerativas/patología , Neuronas/patología , Amoníaco/sangre , Animales , Antígenos Nucleares/metabolismo , Ansiedad/psicología , Apoptosis , Conducta Animal , Caspasa 3/metabolismo , Circulación Cerebrovascular/efectos de los fármacos , Modelos Animales de Enfermedad , Encefalopatía Hepática/patología , Hiperamonemia , Ligadura , Masculino , Proteínas del Tejido Nervioso/metabolismo , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/psicología , Ornitina/análogos & derivados , Ornitina/uso terapéutico , Ratas , Ratas Sprague-Dawley
8.
J Neuroinflammation ; 16(1): 3, 2019 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-30611289

RESUMEN

BACKGROUND: Immunologic abnormalities have been described in peripheral blood and central nervous system of patients suffering from Alzheimer's disease (AD), yet their role in the pathogenesis still remains poorly defined. AIM AND METHODS: We used the triple transgenic mouse model (3xTg-AD) to reproduce Aß (amyloid plaques) and tau (neurofibrillary tangles) neuropathologies. We analyzed important features of the adaptive immune system in serum, primary (bone marrow) as well as secondary (spleen) lymphoid organs of 12-month-old 3xTg-AD mice using flow cytometry and ELISPOT. We further investigated serum cytokines of 9- and 13-month-old 3xTg-AD mice using multiplex ELISA. Results were compared to age-matched non-transgenic controls (NTg). RESULTS: In the bone marrow of 12-month-old 3xTg-AD mice, we detected decreased proportions of short-term reconstituting hematopoietic stem cells (0.58-fold, P = 0.0116), while lymphocyte, granulocyte, and monocyte populations remained unchanged. Our results also point to increased activation of both B and T lymphocytes. Indeed, we report elevated levels of plasma cells in bone marrow (1.3-fold, P = 0.0405) along with a 5.4-fold rise in serum IgG concentration (P < 0.0001) in 3xTg-AD animals. Furthermore, higher levels of interleukin (IL)-2 were detected in serum of 9- and 13-month-old 3xTg-AD mice (P = 0.0018). Along with increased concentrations of IL-17 (P = 0.0115) and granulocyte-macrophage colony-stimulating factor (P = 0.0085), these data support helper T lymphocyte activation with Th17 polarization. CONCLUSION: Collectively, these results suggest that the 3xTg-AD model mimics modifications of the adaptive immunity changes previously observed in human AD patients and underscore the activation of both valuable and harmful pathways of immunity in AD.


Asunto(s)
Inmunidad Adaptativa/fisiología , Enfermedad de Alzheimer/inmunología , Enfermedad de Alzheimer/patología , Citocinas/metabolismo , Linfocitos/patología , Inmunidad Adaptativa/genética , Enfermedad de Alzheimer/genética , Péptidos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/genética , Animales , Médula Ósea/patología , Polaridad Celular/genética , Granulocitos/patología , Humanos , Ratones , Ratones Transgénicos , Monocitos/patología , Mutación/genética , Ovillos Neurofibrilares , Presenilina-1/genética , Bazo/patología , Proteínas tau/genética
9.
Liver Int ; 38(1): 102-112, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28665498

RESUMEN

BACKGROUND & AIMS: Recent studies suggest that heparins reduce liver fibrosis and the risk of decompensation of liver disease. Here, we evaluated the effects of enoxaparin in several experimental models of advanced cirrhosis. METHODS: Cirrhosis was induced in male Sprague-Dawley (SD) rats by: (i) Oral gavage with carbon tetrachloride (CCl4ORAL ), (ii) Bile duct ligation (BDL) and (iii) CCl4 inhalation (CCl4INH ). Rats received saline or enoxaparin s.c. (40 IU/Kg/d or 180 IU/Kg/d) following various protocols. Blood biochemical parameters, liver fibrosis, endothelium- and fibrosis-related genes, portal pressure, splenomegaly, bacterial translocation, systemic inflammation and survival were evaluated. Endothelial dysfunction was assessed by in situ bivascular liver perfusions. RESULTS: Enoxaparin did not ameliorate liver function, liver fibrosis, profibrogenic gene expression, portal hypertension, splenomegaly, ascites development and infection, serum IL-6 levels or survival in rats with CCl4ORAL or BDL-induced cirrhosis. Contrarily, enoxaparin worsened portal pressure in BDL rats and decreased survival in CCl4ORAL rats. In CCl4INH rats, enoxaparin had no effects on hepatic endothelial dysfunction, except for correcting the hepatic arterial dysfunction when enoxaparin was started with the CCl4 exposure. In these rats, however, enoxaparin increased liver fibrosis and the absolute values of portal venous and sinusoidal resistance. CONCLUSIONS: Our results do not support a role of enoxaparin for improving liver fibrosis, portal hypertension or endothelial dysfunction in active disease at advanced stages of cirrhosis. These disease-related factors and the possibility of a limited therapeutic window should be considered in future studies evaluating the use of anticoagulants in cirrhosis.


Asunto(s)
Anticoagulantes/farmacología , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Enoxaparina/farmacología , Hipertensión Portal/prevención & control , Cirrosis Hepática Experimental/prevención & control , Hígado/efectos de los fármacos , Presión Portal/efectos de los fármacos , Animales , Anticoagulantes/toxicidad , Traslocación Bacteriana/efectos de los fármacos , Biomarcadores/sangre , Coagulación Sanguínea/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/fisiopatología , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Células Endoteliales/patología , Enoxaparina/toxicidad , Hipertensión Portal/sangre , Hipertensión Portal/patología , Hipertensión Portal/fisiopatología , Mediadores de Inflamación/sangre , Hígado/metabolismo , Hígado/patología , Circulación Hepática/efectos de los fármacos , Cirrosis Hepática Experimental/sangre , Cirrosis Hepática Experimental/patología , Cirrosis Hepática Experimental/fisiopatología , Masculino , Microcirculación/efectos de los fármacos , Ratas Sprague-Dawley
10.
Metab Brain Dis ; 32(2): 513-518, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27981407

RESUMEN

Muscle mass loss and hepatic encephalopathy (complex neuropsychiatric disorder) are serious complications of chronic liver disease (cirrhosis) which impact negatively on clinical outcome and quality of life and increase mortality. Liver disease leads to hyperammonemia and ammonia toxicity is believed to play a major role in the pathogenesis of hepatic encephalopathy. However, the effects of ammonia are not brain-specific and therefore may also affect other organs and tissues including muscle. The precise pathophysiological mechanisms underlying muscle wasting in chronic liver disease remains to be elucidated. In the present study, we characterized body composition as well as muscle protein synthesis in cirrhotic rats with hepatic encephalopathy using the 6-week bile duct ligation (BDL) model which recapitulates the main features of cirrhosis. Compared to sham-operated control animals, BDL rats display significant decreased gain in body weight, altered body composition, decreased gastrocnemius muscle mass and circumference as well as altered muscle morphology. Muscle protein synthesis was also significantly reduced in BDL rats compared to control animals. These findings demonstrate that the 6-week BDL experimental rat is a relevant model to study liver disease-induced muscle mass loss.


Asunto(s)
Conductos Biliares , Cirrosis Hepática Experimental/patología , Músculo Esquelético/patología , Amoníaco/sangre , Animales , Composición de Base , Modelos Animales de Enfermedad , Ingestión de Alimentos , Encefalopatía Hepática , Hiperamonemia/etiología , Hiperamonemia/patología , Ligadura , Masculino , Proteínas Musculares/metabolismo , Ratas , Ratas Sprague-Dawley , Aumento de Peso
11.
Liver Int ; 34(9): 1322-9, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25354203

RESUMEN

BACKGROUND & AIMS: The pathogenesis of hepatic encephalopathy (HE) is multifactorial and often associated with the development of brain oedema. In addition to ammonia playing a central role, systemic oxidative stress is believed to aggravate the neuropsychological effects of ammonia in patients with chronic liver disease (CLD). The aim of this study was to (i) induce systemic oxidative stress in hyperammonaemic portacaval anastomosed (PCA) rats by inhibiting the antioxidant glutathione using Dimethyl maleate (DEM) and (ii) investigate whether a synergistic relationship between ammonia and oxidative stress contributes to the pathogenesis of brain oedema in CLD. METHODS: Four-week PCA and sham-operated rats received DEM (0.4-4 mg/kg/day) for the last 10 days before sacrifice when oxidative stress markers [reactive oxygen species (ROS) and malondialdehyde (MDA)] were assessed in blood and frontal cortex. Brain water content was measured using a specific gravimetric technique. RESULTS: Dimethyl maleate induced an increase in ROS and MDA in the blood, but not in the brain, of the PCA rats, compared with non-treated PCA rats. This was accompanied with an increase in brain water content (PCA+DEM: 78.45 ± 0.13% vs. PCA: 77.38 ± 0.11%, P < 0.001). Higher doses of DEM induced systemic oxidative stress in sham-operated controls, but brain oedema did not develop. CONCLUSIONS: Dimethyl maleate provoked systemic, not central, oxidative stress in PCA rats, resulting in the development of brain oedema. Independently, hyperammonaemia and systemic oxidative stress do not precipitate brain oedema; therefore, our findings sustain that a synergistic effect between hyperammonaemia and systemic oxidative stress is responsible for the development of brain oedema in HE.


Asunto(s)
Amoníaco/toxicidad , Biomarcadores/metabolismo , Edema Encefálico/fisiopatología , Enfermedad Hepática en Estado Terminal/complicaciones , Encefalopatía Hepática/fisiopatología , Maleatos/farmacología , Estrés Oxidativo/fisiología , Análisis de Varianza , Animales , Edema Encefálico/etiología , Glutatión/antagonistas & inhibidores , Encefalopatía Hepática/etiología , Masculino , Maleatos/administración & dosificación , Malondialdehído/sangre , Estrés Oxidativo/efectos de los fármacos , Derivación Portocava Quirúrgica , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/sangre
12.
Metab Brain Dis ; 29(4): 919-25, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24916505

RESUMEN

Hepatic encephalopathy (HE), a complex neuropsychiatric syndrome, is a frequent complication of liver failure/disease. Increased concentrations of lactate are commonly observed in HE patients, in the systemic circulation, but also in the brain. Traditionally, increased cerebral lactate is considered a marker of energy failure/impairment however alterations in lactate homeostasis may also lead to a rise in brain lactate and result in neuronal dysfunction. The latter may involve the development of brain edema. This review will target the significance of increased cerebral lactate in the pathogenesis of HE.


Asunto(s)
Encéfalo/metabolismo , Encefalopatía Hepática/etiología , Ácido Láctico/metabolismo , Amoníaco/metabolismo , Animales , Edema Encefálico/metabolismo , Ciclo del Ácido Cítrico , Ácido Dicloroacético/uso terapéutico , Evaluación Preclínica de Medicamentos , Encefalopatía Hepática/tratamiento farmacológico , Encefalopatía Hepática/metabolismo , Homeostasis , Humanos , L-Lactato Deshidrogenasa/fisiología , Hepatopatías/complicaciones , Hepatopatías/metabolismo , Complejo Piruvato Deshidrogenasa/metabolismo
13.
J Hepatol ; 60(3): 554-60, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24512824

RESUMEN

BACKGROUND & AIMS: The pathogenesis of brain edema in patients with chronic liver disease (CLD) and minimal hepatic encephalopathy (HE) remains undefined. This study evaluated the role of brain lactate, glutamine and organic osmolytes, including myo-inositol and taurine, in the development of brain edema in a rat model of cirrhosis. METHODS: Six-week bile-duct ligated (BDL) rats were injected with (13)C-glucose and de novo synthesis of lactate, and glutamine in the brain was quantified using (13)C nuclear magnetic resonance spectroscopy (NMR). Total brain lactate, glutamine, and osmolytes were measured using (1)H NMR or high performance liquid chromatography. To further define the interplay between lactate, glutamine and brain edema, BDL rats were treated with AST-120 (engineered activated carbon microspheres) and dichloroacetate (DCA: lactate synthesis inhibitor). RESULTS: Significant increases in de novo synthesis of lactate (1.6-fold, p<0.001) and glutamine (2.2-fold, p<0.01) were demonstrated in the brains of BDL rats vs. SHAM-operated controls. Moreover, a decrease in cerebral myo-inositol (p<0.001), with no change in taurine, was found in the presence of brain edema in BDL rats vs. controls. BDL rats treated with either AST-120 or DCA showed attenuation in brain edema and brain lactate. These two treatments did not lead to similar reductions in brain glutamine. CONCLUSIONS: Increased brain lactate, and not glutamine, is a primary player in the pathogenesis of brain edema in CLD. In addition, alterations in the osmoregulatory response may also be contributing factors. Our results suggest that inhibiting lactate synthesis is a new potential target for the treatment of HE.


Asunto(s)
Edema Encefálico/etiología , Encéfalo/metabolismo , Encefalopatía Hepática/etiología , Ácido Láctico/metabolismo , Hepatopatías/complicaciones , Amoníaco/metabolismo , Animales , Enfermedad Crónica , Glutamina/metabolismo , Encefalopatía Hepática/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley
14.
Neurochem Int ; 62(4): 446-57, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23376027

RESUMEN

Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome that typically develops as a result of acute liver failure or chronic liver disease. Brain edema is a common feature associated with HE. In acute liver failure, brain edema contributes to an increase in intracranial pressure, which can fatally lead to brain stem herniation. In chronic liver disease, intracranial hypertension is rarely observed, even though brain edema may be present. This discrepancy in the development of intracranial hypertension in acute liver failure versus chronic liver disease suggests that brain edema plays a different role in relation to the onset of HE. Furthermore, the pathophysiological mechanisms involved in the development of brain edema in acute liver failure and chronic liver disease are dissimilar. This review explores the types of brain edema, the cells, and pathogenic factors involved in its development, while emphasizing the differences in acute liver failure versus chronic liver disease. The implications of brain edema developing as a neuropathological consequence of HE, or as a cause of HE, are also discussed.


Asunto(s)
Edema Encefálico/fisiopatología , Fallo Hepático/fisiopatología , Enfermedad Aguda , Enfermedad Crónica , Humanos
15.
Metab Brain Dis ; 28(2): 175-8, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23124921

RESUMEN

Although ammonia is considered the main factor involved in the pathogenesis of hepatic encephalopathy (HE), it correlates well with the severity of HE in acute liver failure, but not in chronic liver disease. Oxidative stress is another factor believed to play a role in the pathogenesis of this syndrome; it represents an imbalance between the production and neutralization of reactive oxygen species, which leads to cellular dysfunction. In the setting of liver disease, oxidative stress represents a systemic phenomenon induced by several mechanisms: decreased antioxidant synthesis, increased systemic release of oxidant enzymes, generation of reactive oxygen species, and impaired neutrophil function. High ammonia concentrations induce cerebral oxidative stress, thus contributing to severe hepatic encephalopathy, as observed in acute liver failure. In chronic liver disease, significantly lower degrees of hyperammonemia (<500 µM) do not induce cerebral nor systemic oxidative stress. Data from both animal and human studies sustain that there is a synergistic effect between systemic oxidative stress, and ammonia that is implicated in the pathogenesis of hepatic encephalopathy.


Asunto(s)
Encefalopatía Hepática/fisiopatología , Estrés Oxidativo/fisiología , Animales , Encefalopatía Hepática/metabolismo , Humanos , Hígado/metabolismo , Cirrosis Hepática/etiología , Cirrosis Hepática/metabolismo
16.
Free Radic Biol Med ; 52(7): 1228-35, 2012 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-22300646

RESUMEN

Chronic liver failure leads to hyperammonemia, a central component in the pathogenesis of hepatic encephalopathy (HE); however, a correlation between blood ammonia levels and HE severity remains controversial. It is believed oxidative stress plays a role in modulating the effects of hyperammonemia. This study aimed to determine the relationship between chronic hyperammonemia, oxidative stress, and brain edema (BE) in two rat models of HE: portacaval anastomosis (PCA) and bile-duct ligation (BDL). Ammonia and reactive oxygen species (ROS) levels, BE, oxidant and antioxidant enzyme activities, as well as lipid peroxidation were assessed both systemically and centrally in these two different animal models. Then, the effects of allopurinol (xanthine oxidase inhibitor, 100mg/kg for 10days) on ROS and BE and the temporal resolution of ammonia, ROS, and BE were evaluated only in BDL rats. Similar arterial and cerebrospinal fluid ammonia levels were found in PCA and BDL rats, both significantly higher compared to their respective sham-operated controls (p<0.05). BE was detected in BDL rats (p < 0.05) but not in PCA rats. Evidence of oxidative stress was found systemically but not centrally in BDL rats: increased levels of ROS, increased activity of xanthine oxidase (oxidant enzyme), enhanced oxidative modifications on lipids, as well as decreased antioxidant defense. In PCA rats, a preserved oxidant/antioxidant balance was demonstrated. Treatment with allopurinol in BDL rats attenuated both ROS and BE, suggesting systemic oxidative stress is implicated in the pathogenesis of BE. Analysis of ROS and ammonia temporal resolution in the plasma of BDL rats suggests systemic oxidative stress might be an important "first hit", which, followed by increases in ammonia, leads to BE in chronic liver failure. In conclusion, chronic hyperammonemia and oxidative stress in combination lead to the onset of BE in rats with chronic liver failure.


Asunto(s)
Edema Encefálico/etiología , Modelos Animales de Enfermedad , Enfermedad Hepática en Estado Terminal/complicaciones , Hiperamonemia/etiología , Estrés Oxidativo , Amoníaco/metabolismo , Animales , Barrera Hematoencefálica , Edema Encefálico/patología , Hiperamonemia/patología , Ligadura , Peroxidación de Lípido , Masculino , Derivación Portocava Quirúrgica , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo
17.
Hepatology ; 53(6): 1995-2002, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21384402

RESUMEN

UNLABELLED: The pathogenesis of hepatic encephalopathy is multifactorial, involving gut-derived toxins such as ammonia, which has been demonstrated to induce oxidative stress. Therefore, a primary hepatic encephalopathy treatment target is reducing ammonia production in the gastrointestinal tract. AST-120, an oral adsorbent of engineered activated carbon microspheres with surface areas exceeding 1600 m2/g, acts as a sink for neurotoxins and hepatotoxins present in the gut. We evaluated the capacity of AST-120 to adsorb ammonia in vitro and to lower blood ammonia, oxidative stress and brain edema in cirrhotic rats. Cirrhosis was induced in rats by bile duct ligation for 6 weeks. AST-120 was administered by gavage preventively for 6 weeks (0.1, 1, and 4 g/kg/day). In addition, AST-120 was evaluated as a short-term treatment for 2 weeks and 3 days (1 g/kg/day) and as a sink to adsorb intravenously infused ammonium acetate. In vitro, AST-120 efficiently adsorbed ammonia. Ammonia levels significantly decreased in a dose-dependent manner for all AST-120-treated bile duct-ligated rats (nontreated: 177.3 ± 30.8 µM; AST-120, 0.1 g/kg/day: 121.9 ± 13.8 µM; AST-120, 1 g/kg/day: 80.9 ± 30.0 µM; AST-120, 4 g/kg/day: 48.8 ± 19.6 µM) and significantly correlated with doses of AST-120 (r = -0.6603). Brain water content and locomotor activity normalized after AST-120 treatments, whereas arterial reactive oxygen species levels remained unchanged. Furthermore, AST-120 significantly attenuated a rise in arterial ammonia after ammonium acetate administration (intravenously). CONCLUSION: AST-120 treatment decreased arterial ammonia levels, normalized brain water content and locomotor activity but did not demonstrate an effect on systemic oxidative stress. Also, AST-120 acts as an ammonia sink, efficiently removing blood-derived ammonia. Additional studies are warranted to evaluate the effects of AST-120 on hepatic encephalopathy in patients with advanced liver disease.


Asunto(s)
Amoníaco/sangre , Conductos Biliares/cirugía , Edema Encefálico/etiología , Edema Encefálico/prevención & control , Carbono/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/etiología , Óxidos/uso terapéutico , Acetatos/administración & dosificación , Acetatos/efectos adversos , Animales , Edema Encefálico/fisiopatología , Carbono/administración & dosificación , Carbono/farmacología , Relación Dosis-Respuesta a Droga , Infusiones Intravenosas , Ligadura/efectos adversos , Masculino , Microesferas , Modelos Animales , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Óxidos/administración & dosificación , Óxidos/farmacología , Ratas , Ratas Sprague-Dawley
18.
Metab Brain Dis ; 25(1): 11-5, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20195725

RESUMEN

Ammonia is neurotoxic and believed to play a major role in the pathogenesis of hepatic encephalopathy (HE). It has been demonstrated, in vitro and in vivo, that acute and high ammonia treatment induces oxidative stress. Reactive oxygen species (ROS) are highly reactive and can lead to oxidization of proteins resulting in protein damage. The present study was aimed to assess oxidative status of proteins in plasma and brain (frontal cortex) of rats with 4-week portacaval anastomosis (PCA). Markers of oxidative stress, 4-hydroxy-2-nonenal (HNE) and carbonylation were evaluated by immunoblotting in plasma and frontal cortex. Western blot analysis did not demonstrate a significant difference in either HNE-linked or carbonyl derivatives on proteins between PCA and sham-operated control rats in both plasma and frontal cortex. The present study suggests PCA-induced hyperammonemia does not lead to systemic or central oxidative stress.


Asunto(s)
Encefalopatía Hepática/metabolismo , Encefalopatía Hepática/fisiopatología , Hiperamonemia/metabolismo , Hiperamonemia/fisiopatología , Estrés Oxidativo/fisiología , Especies Reactivas de Oxígeno/metabolismo , Aldehídos/análisis , Aldehídos/sangre , Amoníaco/análisis , Amoníaco/sangre , Amoníaco/líquido cefalorraquídeo , Animales , Biomarcadores/análisis , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Western Blotting , Encéfalo/metabolismo , Encéfalo/fisiopatología , Modelos Animales de Enfermedad , Lóbulo Frontal/metabolismo , Lóbulo Frontal/fisiopatología , Hiperamonemia/complicaciones , Fallo Hepático Agudo/complicaciones , Fallo Hepático Agudo/metabolismo , Fallo Hepático Agudo/fisiopatología , Masculino , Derivación Portocava Quirúrgica/efectos adversos , Carbonilación Proteica/fisiología , Ratas , Ratas Sprague-Dawley
19.
Metab Brain Dis ; 24(1): 95-102, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19104924

RESUMEN

Elevated concentrations of ammonia in the brain as a result of hyperammonemia leads to cerebral dysfunction involving a spectrum of neuropsychiatric and neurological symptoms (impaired memory, shortened attention span, sleep-wake inversions, brain edema, intracranial hypertension, seizures, ataxia and coma). Many studies have demonstrated ammonia as a major player involved in the neuropathophysiology associated with liver failure and inherited urea cycle enzyme disorders. Ammonia in solution is composed of a gas (NH(3)) and an ionic (NH(4) (+)) component which are both capable of crossing plasma membranes through diffusion, channels and transport mechanisms and as a result have a direct effect on pH. Furthermore, NH(4) (+) has similar properties as K(+) and, therefore, competes with K(+) on K(+) transporters and channels resulting in a direct effect on membrane potential. Ammonia is also a product as well as a substrate for many different biochemical reactions and consequently, an increase in brain ammonia accompanies disturbances in cerebral metabolism. These direct effects of elevated ammonia concentrations on the brain will lead to a cascade of secondary effects and encephalopathy.


Asunto(s)
Amoníaco/metabolismo , Encéfalo/metabolismo , Encefalopatía Hepática/metabolismo , Hiperamonemia/metabolismo , Adenosina Trifosfatasas/metabolismo , Animales , Encéfalo/fisiopatología , Proteínas de Transporte de Catión/metabolismo , Membrana Celular/metabolismo , Encefalopatía Hepática/fisiopatología , Humanos , Hiperamonemia/fisiopatología , Potencial de la Membrana Mitocondrial/fisiología , Neuronas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA